BioCatalystWatch
CURXWorkspace / CURX / OverviewCompany library
Curanex Pharmaceuticals Inc logo

Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc (CURX)

Website

Price
Market cap
Next catalystPhase 1 clinical development planned to initiate in Australia in Q4 2026, subject to completion of required studies and regulatory clearancePhyto-N — ulcerative colitis · Trial initiationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

Phyto-N

PreINDP2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Clinical

Upcoming clinical milestones

Phyto-N

PreINDP2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

History / paused

Phyto-N

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

CURX PR & News

PR & News

CURX SEC archive